GT Biopharma raises $7.45M via convertible preferred
GT Biopharma Inc raised $7.45M through Series M convertible preferred stock and warrants, with full ratchet protection. Insiders pledged votes to help secure approvals for the financing and share increases as GTB-5550 advances in Phase 1a dose escalation for 25 patients.
45M through Series M convertible preferred stock and warrants that include full-ratchet protection. Insiders pledged votes to secure approvals for the financing and share increases as the company advances GTB-5550 through Phase 1a dose escalation into a 25-patient study.